Contineum Therapeutics (CTNM) Free Cash Flow: 2023-2025
Historic Free Cash Flow for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to -$12.3 million.
- Contineum Therapeutics' Free Cash Flow fell 96.69% to -$12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.8 million, marking a year-over-year decrease of 55.36%. This contributed to the annual value of -$33.4 million for FY2024, which is 276.18% down from last year.
- According to the latest figures from Q3 2025, Contineum Therapeutics' Free Cash Flow is -$12.3 million, which was up 21.71% from -$15.7 million recorded in Q2 2025.
- In the past 5 years, Contineum Therapeutics' Free Cash Flow ranged from a high of $40.6 million in Q2 2023 and a low of -$15.7 million during Q2 2025.
- In the last 3 years, Contineum Therapeutics' Free Cash Flow had a median value of -$8.6 million in 2024 and averaged -$5.2 million.
- Data for Contineum Therapeutics' Free Cash Flow shows a peak YoY increase of 5.86% (in 2024) and a maximum YoY decrease of 121.20% (in 2024) over the last 5 years.
- Quarterly analysis of 3 years shows Contineum Therapeutics' Free Cash Flow stood at -$11.0 million in 2023, then rose by 5.86% to -$10.4 million in 2024, then slumped by 96.69% to -$12.3 million in 2025.
- Its Free Cash Flow stands at -$12.3 million for Q3 2025, versus -$15.7 million for Q2 2025 and -$14.5 million for Q1 2025.